PTT-002

PTT-002 is a preclinical-stage drug candidate developed by Pyrotech Therapeutics for the treatment of sepsis. Pyrotech Therapeutics specializes in the discovery and development of therapeutics targeting programmed cell death pathways, specifically pyroptosis. PTT-002 is designed to address the hyper-inflammatory response associated with sepsis, potentially by inhibiting key proteins involved in the inflammatory signaling cascade, such as those in the inflammasome or gasdermin families. By modulating these pathways, PTT-002 aims to prevent the systemic cytokine release and tissue damage characteristic of septic shock.